These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B, IBSEN Study Group. Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104 [Abstract] [Full Text] [Related]
7. [The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease]. López Morante AJ, Sáez-Royuela F, Yuguero del Moral L, Martín Lorente JL, Ojeda Giménez C. Rev Esp Enferm Dig; 1993 Jan; 83(1):5-9. PubMed ID: 8452705 [Abstract] [Full Text] [Related]
8. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT, Dotan N, Halpern Z. Gastroenterology; 2006 Aug; 131(2):366-78. PubMed ID: 16890590 [Abstract] [Full Text] [Related]
11. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A. Aliment Pharmacol Ther; 2004 Nov 15; 20(10):1143-52. PubMed ID: 15569117 [Abstract] [Full Text] [Related]
12. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Folwaczny C, Wiebecke B, Loeschke K. Am J Gastroenterol; 1999 Jun 15; 94(6):1551-5. PubMed ID: 10364024 [Abstract] [Full Text] [Related]
15. Crohn's disease in the Jewish population of Tel-Aviv-Yafo. Epidemiologic and clinical aspects. Rozen P, Zonis J, Yekutiel P, Gilat T. Gastroenterology; 1979 Jan 15; 76(1):25-30. PubMed ID: 758145 [Abstract] [Full Text] [Related]
16. Defense mechanisms in inflammatory bowel disease. Hyphantis TN, Triantafillidis JK, Pappa S, Mantas C, Kaltsouda A, Cherakakis P, Alamanos Y, Manousos ON, Mavreas VG. J Gastroenterol; 2005 Jan 15; 40(1):24-30. PubMed ID: 15692786 [Abstract] [Full Text] [Related]
18. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. Schinzari F, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D, Cardillo C. Clin Pharmacol Ther; 2008 Jan 15; 83(1):70-6. PubMed ID: 17507924 [Abstract] [Full Text] [Related]
19. Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events. Papa A, Danese S, Piccirillo N, Toriani-Terenzi C, Bartolozzi F, Piscaglia AC, Grillo A, Leone G, Gentiloni-Silveri N, Gasbarrini G, Gasbarrini A. Hepatogastroenterology; 2003 Jan 15; 50(49):132-5. PubMed ID: 12630008 [Abstract] [Full Text] [Related]
20. Zinc metabolism and taste acuity in renal transplant recipients. Mahajan SK, Abraham J, Hessburg T, Prasad AS, Migdal SD, Abu-Hamdan DK, Briggs WA, McDonald FD. Kidney Int Suppl; 1983 Dec 15; 16():S310-4. PubMed ID: 6376919 [Abstract] [Full Text] [Related] Page: [Next] [New Search]